Actuate Therapeutics CEO Daniel M. Schmitt reports acquiring $49,999.62 in common shares
ACTU•Actuate Therapeutics CEO Daniel M. Schmitt purchased 140,844 common shares at $0.355 each, increasing his direct holdings to 442,560 shares. He also acquired immediately exercisable warrants for 70,422 shares at $0.45 each, expiring October 28, 2031.
1. Share purchase
Actuate Therapeutics President, CEO and Director Daniel M. Schmitt purchased 140,844 common shares at $0.355 each. His direct common stock holdings increased to 442,560 shares.
2. Warrants acquired
Schmitt also acquired warrants to purchase 70,422 common shares at an exercise price of $0.45 per share. The warrants are immediately exercisable and expire October 28, 2031.
